Grace A L Hampson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3362358/publications.pdf

Version: 2024-02-01

932766 1125271 15 502 10 13 citations g-index h-index papers 15 15 15 758 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Diagnosis and management of varicose veins in the legs: summary of NICE guidance. BMJ, The, 2013, 347, f4279-f4279.	3.0	127
2	Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare. European Journal of Health Economics, 2019, 20, 427-438.	1.4	85
3	Gene therapy: evidence, value and affordability in the US health care system. Journal of Comparative Effectiveness Research, 2018, 7, 15-28.	0.6	84
4	Real-world evidence for coverage decisions: opportunities and challenges. Journal of Comparative Effectiveness Research, 2018, 7, 1133-1143.	0.6	59
5	Prevention and management of pressure ulcers in primary and secondary care: summary of NICE guidance. BMJ, The, 2014, 348, g2592-g2592.	3.0	51
6	Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders' Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL). PharmacoEconomics - Open, 2018, 2, 153-163.	0.9	22
7	An economic analysis of human milk supplementation for very low birth weight babies in the USA. BMC Pediatrics, 2019, 19, 337.	0.7	17
8	The cost-effectiveness of shopping to a predetermined grocery list to reduce overweight and obesity. Nutrition and Diabetes, 2013, 3, e77-e77.	1.5	16
9	Does a biomedical research centre affect patient care in local hospitals?. Health Research Policy and Systems, 2017, 15, 2.	1.1	14
10	A framework to guide the optimal development and use of real-world evidence for drug coverage and formulary decisions. Journal of Comparative Effectiveness Research, 2018, 7, 1145-1152.	0.6	12
11	Cost-effectiveness analysis: role and implications. Phlebology, 2013, 28, 135-140.	0.6	7
12	A Multinational European Study of Patient Preferences for Novel Diagnostics to ManageÂAntimicrobial Resistance. Applied Health Economics and Health Policy, 2020, 18, 69-79.	1.0	5
13	ASSESSING VALUE, BUDGET IMPACT, AND AFFORDABILITY IN ASIA. International Journal of Technology Assessment in Health Care, 2017, 33, 315-322.	0.2	3
14	Authors' Reply to Hays: "A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance― Applied Health Economics and Health Policy, 2020, 18, 459-460.	1.0	0
15	Exclusive human milk diet for veryÂpretermÂbabies inÂEngland: protocol for a cost-effectiveness and budget impact analysis. F1000Research, 0, 10, 21.	0.8	0